Inaugural Humana Cognitive Games to Celebrate Healthy Aging and Inspire Whole-Person Wellness
'Trying new things – whether it's a hobby, an instrument or a puzzle – stimulates the brain and helps protect against mental decline.' -Dr. Isabel Souffront
Share
This new virtual challenge debuts as part of the 2025 National Senior Games kicking off in Des Moines, Iowa, later this month. This year marks the 10 th consecutive time Humana has served as the presenting sponsor for the biennial Olympic-style event, which brings together more than 12,000 athletes aged 50 and older for competition, inspiration and camaraderie.
With the launch of the Humana Cognitive Games, Humana is expanding its celebration of healthy aging beyond the physical multi-sport event to engage older adults across the country – competitive athlete or not.
During the nationwide virtual event, open through August 11 at HumanaGames.com, all are invited to learn more about actions they can take to give their brain a workout. The challenge features a variety of brain-training activities, lifestyle tips and educational content designed to exercise the mind and foster social connection.
Research shows that engaging in regular mental exercises can have both short- and long-term benefits for brain health, helping older adults stay independent and potentially reduce the risk of dementia and cognitive decline.
'Healthcare starts long before you step into a doctor's office – it begins at home with daily choices we make to take care of our bodies and minds,' said George Renaudin, Humana's President of Insurance. 'At Humana, we are committed to proactive, preventive care – from wellness checks and screenings to personal healthy habits – that can help improve health outcomes. Because for many Americans, true health means the freedom to live life on their own terms.'
This message echoes findings from Humana's recent survey conducted with Morning Consult, which revealed that 78% of adults aged 65 and older prioritize independence over longevity without self-sufficiency. Yet, while 94% say their health and well-being is a top priority, fewer than half say they consistently prioritize consuming a healthy diet and exercising. The Humana Cognitive Games aim to bridge that gap by making whole-health activities engaging and accessible.
'You've got to exercise your brain. It's like anything in life. If you can strengthen that muscle, it will help keep you sharp,' says Isabel Souffront, MD, Chief Medical Officer for Conviva Senior Primary Care in Broward County, Florida. 'Trying new things – whether it's a hobby, an instrument or a puzzle – stimulates the brain and helps protect against mental decline.'
For more information about the Humana Cognitive Games and how to participate, visit HumanaGames.com.
About Humana
Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we strive to make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and CenterWell.com.
Additional Information
This information is provided for educational purposes only. It is not to be used for medical advice, diagnosis or treatment. Consult your healthcare provider if you have questions or concerns. Consult your doctor before beginning any new diet or exercise regimen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14 minutes ago
- Business Wire
Herbalife CEO and CFO to Participate in Barclays Global Consumer Staples Conference on September 2
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced Stephan Gratziani, Chief Executive Officer, and John DeSimone, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Consumer Staples Conference on Tuesday, September 2, 2025 at 4:30 p.m. ET (1:30 p.m. PT). A link to the live webcast will be available under the Investor Relations section of Herbalife's website at A replay of the webcast will also be available at the same website following the completion of the event and for six months thereafter. About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit
Business Wire
14 minutes ago
- Business Wire
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide. 'Although retinitis pigmentosa is a relentlessly progressive condition that has been recognized for decades as a significant cause of blindness, there are no approved therapies for most forms of the disease,' stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. 'Fast Track Designation in conjunction with the previously announced Orphan Drug Designation underscores the potential for ADX-2191 to address an unmet need in the field of ophthalmology and creates the framework for ADX-2191, if approved, to reach patients promptly.' The potential activity of ADX-2191 in retinitis pigmentosa is supported by results from a Phase 2 clinical trial, announced in 2023, which demonstrated improvements from baseline in retinal sensitivity following treatment. A planned Phase 2/3 clinical trial of ADX-2191 in retinitis pigmentosa is expected to initiate in 2025. Fast Track Designation is designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address an unmet medical need. Fast Track Designation enables frequent FDA interactions and may allow for rolling review, priority review, or accelerated approval if relevant criteria are met. About ADX-2191 ADX-2191 (methotrexate injection, USP) is a sterile, non-compounded intravitreal formulation of methotrexate for the potential treatment of specific rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa. The ADX-2191 intravitreal formulation is preservative-free, is designed to be vitreous-compatible, and is optimized for excipient composition, viscosity, density, tonicity, pH, concentration, and volume of administration. ADX-2191 has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa, Fast Track Designation for the treatment of retinitis pigmentosa, and EMA Orphan Designation for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa, and the treatment of primary large B-Cell lymphomas of immune privileged sites, including primary vitreoretinal lymphoma. About Retinitis Pigmentosa Retinitis pigmentosa is a group of rare genetic eye diseases characterized by retinal cell death and loss of vision. There are currently no approved treatments for most forms of retinitis pigmentosa. In vivo preclinical research has identified the activity of methotrexate in inducing misfolded rhodopsin (a visual cycle protein) clearance, suggesting the potential of ADX‑2191 to treat genetic forms of retinitis pigmentosa that are characterized by misfolded rhodopsin. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX‑248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. Safe Harbor Statement This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra's future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for ADX-2191; and the outcome and timing of any clinical trials of ADX-2191. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' "could," 'can,' 'would,' 'expect,' 'believe,' 'anticipate,' 'project,' 'on track,' 'scheduled,' 'target,' 'design,' 'estimate,' 'predict,' 'contemplates,' 'likely,' 'potential,' 'continue,' 'ongoing,' 'aim,' 'plan,' or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra's product candidates, including as a result of the FDA not accepting Aldeyra's regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra's product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra's product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; uncertainty as to Aldeyra's ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra's product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's commercialization, marketing and manufacturing capabilities and strategy; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's ability to successfully integrate acquisitions into its business; Aldeyra's expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra's business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it operates; and other factors that are described in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31, 2024, and Aldeyra's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC website at Additional factors may be described in those sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, expected to be filed with the SEC in the fourth quarter of 2025, and Aldeyra's other filings with the SEC. In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Business Wire
14 minutes ago
- Business Wire
CorriXR Therapeutics Secures $1M Investment from State of Delaware
NEWARK, Del.--(BUSINESS WIRE)-- CorriXR Therapeutics, Inc., a pioneering oncology-focused biotherapeutics company, has announced a significant milestone with a $1M investment from the State of Delaware. This funding will be instrumental in advancing CorriXR's lead program aimed at developing next-generation treatments for solid tumors, with particular focus on head and neck, and lung cancers. This investment not only underscores the potential of CorriXR's cutting-edge therapies but also highlights Delaware's commitment to supporting innovative early-stage companies. This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions. Share "We're excited to have the State of Delaware participate in our Series A financing round as we advance toward our first-in-human clinical trial,' said Eric Kmiec, Ph.D., founder & CEO of CorriXR. 'This investment will be critical as we complete preclinical studies, scale-up manufacturing, and prepare our investigational new drug (IND) submission.' The State of Delaware's investment in CorriXR is the first $1M investment from the Delaware Accelerator & Seed Capital Program (DASCP), one of four programs awarded under the State Small Business Credit Initiative (SSBCI) federal program from the U.S. Treasury Department. The Division of Small Business is administering Delaware's $60.9 million SSBCI award aimed at providing access to capital for start-up and early-stage businesses. 'Our first $1 million investment is proof that Delaware's path to becoming the Mid-Atlantic hub for Innovation is well underway,' said Delaware Division of Small Business Director CJ Bell. 'Supporting companies like CorriXR to scale isn't just good business – it's the blueprint for turning that vision into reality.' 'This is how Delaware wins the future, with CorriXR demonstrating the power of turning research into real solutions," said Delaware Governor Matt Meyer. "By working closely with experts at the Gene Editing Institute, CorriXR is making promising CRISPR therapies a reality for patients faster than ever. This is exactly why the SSBCI program exists—because supporting innovation today means better treatments, stronger businesses, and a brighter future for Delaware." About CorriXR Therapeutics CorriXR is developing genetic medicines to transform the treatment of solid tumors. CorriXR's patented non-viral gene editing tool disables transcription factor NRF2, which controls 200+ genes responsible for creating a pro-oncogenic tumor microenvironment. Knockout of NRF2 disrupts cancer cell survival mechanisms and sensitizes them to standard of care, and is being developed as a monotherapy, neoadjuvant or in combination with chemotherapy, radiotherapy, or immunotherapy. CorriXR's platform has potential applications in over 30 types of squamous cell carcinomas by improving treatment efficiency at lower doses, increasing patient eligibility, and reducing dropouts due to side effects—ultimately leading to improved patient outcomes. Learn more at
